【摘要】 目的 :探讨膦甲酸钠 (可耐 )的临床疗效及毒副作用。方法 :治疗慢性乙型肝炎患者共 5 6例 ,其中 2 9例应用膦甲酸钠 2 .4g静滴 ,bid ,共用 2 8d ,另 2 7例同时合用干扰素治疗 ,分别于治疗前、治疗 14d和治疗 2 8d检测患者肝功能及乙肝病毒复制指标 (HBeAg ,HBV DNA) ,同时观察患者症状、体征的改变及药物的不良反应。结果 :5 6例慢性乙型肝炎中 ,2 9例单用膦甲酸钠组HBeAg ,HBV DNA分别阴转 8例 (2 7.6 % )和 16例 (5 5 .2 % ) ;2 7例合用干扰素组HBeAg ,HBV DNA分别阴转 6例 (2 2 .2 % )和 14例 (5 1.9% )。 5 6例患者在治疗结束时肝功能均有不同程度的好转 ;不良反应主要表现为乏力、纳差、恶心、头痛、腰痛等 ,均不影响治疗。结论 :膦甲酸钠抗乙肝病毒疗效肯定 ,疗程短 ,病毒指标阴转快 ,同时具有护肝、降酶、退黄及改善症状的作用 ,单用膦甲酸钠与合用干扰素者抗病毒的近期疗效相近 ,远期有待追踪观察。更多还原

【Abstract】 Objective:To study the clinical efficacy and safety of foscarnet sodium.Methods:56 patients with hepatitis B were randomly divided to receive twice daily 2.4g foscarnet sodium infusion for 28 d( n =29) or foscarnet sodium plus interferon α-1b( n =27).Liver function and viral replication quota (HBeAg and HBV-DNA) were measured at the start and at the 14 d and 28 d of treatment .Side effects and changes in condition were observed.Results:The negative turnover rate of HBeAg and HBV-DNA were 27.6%( n =8) and 55.2%( n =16) respectively in foscarnet sodium group in comparison with 22.2% ( n =6)and 51.9%( n =14) respectively in foscarnet sodium plus α-interferon group.The liver function in all patients were improved in varied degrees and the side effects such as fatigue,loss in appetite,nausea,headache,and lambago were tolerable.Conclusion:The short-term efficacy of foscarnet sodium and foscarnet sodium plus α-interferon are simillar in terms of viral negative turnover rate and in improvement in conditions but long-term efficacy need to be observed further. [更多还原